When and how should age influence treatment

Session Track

Head and neck cancer, excl. thyroid


08:30 – 09:20 Type: Educational session Title: The emerging role of immunotherapy in the curative setting


08:35 – 08:50 Immune landscape in head and neck cancer: Rationale and opportunities for integrating immunotherapy in curative treatment protocols



Time: 17:30 – 18:30

Location: Channel 3


860MO – Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC)


862MO – Gene expression profile differentiates short-term and long-term survivors with immunotherapy in patients with recurrent/metastatic head and neck cancer


865MO – RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation




869P – Nivolumab (Nivo) and ipilimumab (Ipi) combined with radiotherapy (RT) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): Updated results of a pilot study

Presentation Number



928TiP – Induction versus adjuvant gemcitabine/cisplatin in locally advanced non-metastatic nasopharyngeal carcinoma: A randomised phase III trial

Presentation Number